推荐产品
等级
pharmaceutical primary standard
API类
levothyroxine
制造商/商品名称
USP
mp
223 °C (dec.) (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O
InChI
1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1
InChI key
XUIIKFGFIJCVMT-LBPRGKRZSA-N
基因信息
human ... THRA(7067) , THRB(7068)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Levothyroxine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Levothyroxine Sodium
- Levothyroxine Sodium Tablets
- Levothyroxine Sodium Oral Powder
- Liothyronine Sodium
- Thyroid
- Thyroid Tablets
- Liothyronine Sodium Tablets
生化/生理作用
L甲状腺素 (T4) 和三碘代-L-甲状腺原氨酸 (T3) 为含碘激素，由甲状腺卵泡细胞中的甲状腺球蛋白制备。这些激素对代谢率的刺激以及对生长发展的调节似乎归因于它们对 DNA 转录的作用，进而影响蛋白质的合成。
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险声明
危险分类
STOT RE 1
靶器官
Thyroid,Cardio-vascular system,Kidney
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Levothyroxine Sodium
United States Pharmacopeia, 45(2) (2020)
Levothyroxine Sodium Tablets
United States Pharmacopeia, 39(1), 3418-3418 (2023)
B Velkeniers et al.
Human reproduction update, 19(3), 251-258 (2013-01-19)
BACKGROUND Previous meta-analyses of observational data indicate that pregnant women with subclinical hypothyroidism have an increased risk of adverse pregnancy outcome. Potential benefits of levothyroxine (LT4) supplementation remain unclear, and no systematic review or meta-analysis of trial findings is available
Michaela Granfors et al.
Obstetrics and gynecology, 124(1), 10-15 (2014-06-06)
To evaluate the efficacy of a targeted thyroid testing approach during pregnancy in clinical practice. This is a retrospective cohort study performed within Uppsala County, Sweden. Data were derived from the population-based Uppsala Biobank of Pregnant Women, in which blood
Shannon E Scratch et al.
Pediatrics, 133(4), e955-e963 (2014-04-02)
Preterm infants commonly have transient hypothyroxinemia of prematurity after birth, which has been associated with deficits in general intellectual functioning, memory, attention, and academic achievement. However, research has predominantly focused on thyroxine levels in the first 2 weeks of life
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门